Anadys Pharmaceuticals Begins Phase II Study Dosing of ANA598

Anadys Pharmaceuticals Begins Phase II Study Dosing of ANA598

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that dosing has begun in a Phase II trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). The study will evaluate ANA598 over 12 weeks, taken in combination with pegylated interferon-alpha and ribavirin, in treatment naïve HCV patients. ANA598 is an investigational, oral, nonnucleoside polymerase inhibitor. Anadys has completed three Phase I clinical studies of ANA598 that have demonstrated potent antiviral activity and good tolerability.

Read the release.